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     ABSTRACT 
Background: 
In CKD patient’s prolactin clearance & production are altered; this causes 
Hyperprolactinemia in CKD patients. 
CKD is associated with increased risk of CAHD.Emerging evidence suggests that 
prolactin plays a major role in atherosclerotic process.  
Objectives: 
To study the occurrence of Hyperprolactinemia in CKD patients. 
 To study the links between hyperprolactinemia in CKD patients & occurrence of 
CAHD in them. 
Methodology: 
We conducted an observational study in 50 CKD patients. Fasting serum prolactin 
levels were measured in them; Incidence of CAHD was evaluated in them using 
ECG & ECHO. 
Results: 
In our study among the 50 CKD patients, 28 patients had Hyperprolactinemia 
which is about 56% of the study population. Statistical analysis using T test 
showed significant association to exist between Hyperprolactinemia & CKD. In 
our study among the 28 CKD patients with Hyperprolactinemia 17 patients were 
diagnosed to have CAHD; this is about 60.7% .Statistical analysis using Chi 
Square test showed significant association to exist between Hyperprolactinemia in 
CKD patients & Occurence of CAHD among them. 
Conclusion: 
Serum prolactin levels are increased in patients with CKD. 
This hyperprolactinemia in CKD patients is associated with increased risk of 
CAHD in them. 
Keywords:  Prolactin,Hyperprolactinemia,CKD&CAHD. 
1 
 
 
INTRODUCTION 
 
Chronic Kidney Disease is characterized by irreversible loss of 
renal function leading to excretory, metabolic and synthetic failure 
culminating in accumulation of non – protein nitrogenous substances and 
present with varied clinical manifestations. 
End stage renal disease [ESRD] is described as terminal stage in 
chronic kidney disease that without renal replacement would result in 
death. 
Despite of various etiologies, CKD is the final common pathway of 
irreversible destruction of nephrons ultimately resulting in alteration of 
“MILIEU INTERIOR” that affects every system in the body. 
Prolactin is a hormone secreted mainly by anterior pituitary gland. 
In addition prolactin is also secreted by various tissues in the body. Main 
action of Prolactin is to control breast development and lactation in 
women. The function of prolactin in men remains to be studied. 
Chronic Kidney Disease is characterized by elevation of serum 
Prolactin levels . Prevalence of hyperprolactinemia in Chronic Kidney 
Disease varies from 30%to 65%1-3.Prolactin clearance is reduced in 
2 
 
Chronic Kidney Disease8. Prolactin production is altered in Chronic 
Kidney Disease9,10.Prolactin’s Biological activity is also increased4. 
With progression of Chronic Kidney Disease serum prolactin level 
also increases. This elevation of serum prolactin level seems to correlate 
with serum creatinine. 
In Male CKD patients Hyperprolactinemia is associated with 
sexual dysfunction5. Hyperprolactinemia is associated with loss of libido 
.Hyperprolactinemia is associated with impaired erection potency5. High 
prolactin levels may be implicated for this abnormality. This may 
contribute to gynaecomastia and sexual dysfunction in male CKD 
patients. 
Hyperprolactinemia is also common among female CKD patients. 
Hyperprolactinemia in female CKD patients is a well – known cause of 
galactorrhoea and gonadal disturbances with menstrual irregularities, 
commonly amenorrhoea5 .Other menstrual irregularities including 
anovulatory cycles or oligomenorrhoea are more frequent in 
hyperprolactinemic  female CKD patients. 
Several studies conducted recently are showing that prolactin may 
have several biologic actions that participate in the atherosclerotic 
process. Elevated serum prolactin levels lead to insulin resistance6. 
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Hyperprolactinemia is associated with increased inflammatory processes6. 
Elevated serum level of prolactin is associated with endothelial 
dysfunction6. Hyperprolactinemia is found in patients with essential 
hypertension7. Hyperprolactinemia is found during the acute phase of 
coronary syndromes11. Hyperprolactinemia is found during ischemic 
strokes & transient ischemic attacks12,13. Hyperprolactinemia is found in 
preeclampsia also14,15. This hyperprolactinemia is found to play a 
causative role in the heart failure that accompanies post partum 
cardiomyopathy16. Hyperprolactinemia in men with erectile dysfunction 
is associated with increased incidence of coronary artery disease17. 
Recent evidences are pointing to the presence of receptors for Prolactin in 
the atherosclerotic plaques18,19. 
The implications of hyperprolactinaemia in CKD are not well 
known yet. Chronic Kidney Disease is characterized by accelerated 
atherosclerotic processes20,21 .This in long term leads to increased 
occurrence of coronary artery disease among this population20,21. Elevated 
levels of serum prolactin which occurs in Chronic Kidney Disease may 
contribute to vascular derangements .This might lead to worse 
cardiovascular outcomes among CKD patients4. 
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This was undertaken as a clinical and biochemical study of serum 
prolactin levels in CKD patients and the incidence of CAHD among them 
were assessed in the department of Internal medicine at Thanjavur 
Medical College Hospital in Thanjavur. 
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AIMS OF THE STUDY 
 
1] To study the association between Chronic Kidney Disease 
and hyperprolactinemia. 
2] To study the incidence of Coronary Artery Heart Disease 
among  the  CKD  patients  with  hyperprolactinemia . 
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REVIEW OF LITERATURE 
CELL OF ORIGIN 
 
Prolactin [PRL] is a 198 – amino acid poly peptide hormone. It’s 
molecular weight is  22000.It is synthesized in the lactotroph cells of 
pituitary gland .These cells are otherwise called as mammotrophs.In 
human beings irrespective of sex about 15-25%of pituitary mass is made 
up of this lactotroph cells22. Hyperplasia of these lactotroph cells occur 
during pregnancy23,24. Hyperplasia of lactotroph cells also occur during 
lactation  period23,24. 
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                        PROLACTIN GENE   
 
 
Prolactin gene in the humans is located on chromosome 
626.Whereas those of related hormones GH and human placental lactogen 
[HPL, also known as human chorionic somatomammotrophin or HCS] 
are located on chromosome 1725. 
Numbers of factors regulate the transcription of Prolactin gene. 
Estrogen directly acts on the prolactin gene and facilitates its 
transcription27,28. 
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Thyroid hormone suppresses the prolactin gene transcription both 
directly and indirectly29.Glucocorticoids exert an inhibitory action on 
PRL synthesis and gene transcription30. Increase in intracellular cAMP 
result in an increase in PRL gene transcription31,32. Dopamine, acts 
through the D2 receptor. It leads to inhibition of adenylyl cyclase33,34.This 
leads to reduction in the level of intracellular cAMP.VIP stimulates 
adenylyl cyclase35.This increases  intracellular cAMP level. This leads to 
Release of prolactin.A number of factors like TRH, Angiotensin II, and 
Dopamine affect PRL secretion through phosphoinositide / arachidonate 
pathway36. Increase in intracellular calcium level results in PRL gene 
transcription, PRL synthesis and release. 
  HORMONE BIOSYNTHESIS 
 
 
Despite evolution from an ancestral hormone common to GH and 
human placental lactogen [Hpl], PRL shares only 16% of its residues 
with former and 13% with hPL. 
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The primary translation product of the human PRL gene is 227 
amino acids in length, consisting of a 28 amino acid signal peptide and a 
199 amino acid hormone with a molecular mass of 23 kDa37. 
The Prolactin molecule has three disulfide bonds. This results in 
folding of the prolactin molecule.The Prolactin molecule undergoes 
number of post translational modifications. This includes cleavage, 
polymerization, glycosylation, phosphorylation & degradation. Thus final 
Prolactin molecule is variable depending on the degree of post 
translational modifications. Thus different assays for prolactin 
measurement give various results because of this post translational 
modification. 
GLYCOSYLATED FORMS 
 Glycosylation of human prolactin occurs38 .The glycosylated 
variants account for 13% to 25% of pituitary PRL and 50%to 100% of 
10 
 
circulating PRL39. Glycosylated PRLs are less immunoreactive in the 
routine PRL RIA, bind less well to the PRL receptor and are less 
bioactive, using a variety of bioassays40. Interestingly, during pregnancy, 
subsequent lactation and pathologic hyperprolactinemic states, when 
there is a high PRL secretion rate, the relative amount of non 
glycosylated PRL increases compared to other times. 
 
PHOSPHORYLATED FORMS 
 Phosphorylated forms of PRL are found in rat and bovine blood. 
Whether this process occurs in humans is unknown. 
Prolactin Synthesis: 
Prolactin synthesis occurs in following organs: 
 
 
 
 
DECIDUAL PROLACTIN 
 Serum Prolactin levels in mother’s blood rise during 
pregnancy .This Prolactin in mother’s blood is secreted by Pituitary 
gland. High levels of Prolactin concentration are found in amniotic fluid 
Pituitary Lymphocytes 
Deciduas Leukocytes 
Myometrium Prostate 
Breast  
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also41. Early biochemical studies found that amniotic fluid PRL was 
identical to serum PRL biologically, chemically and immunologically42. 
Through several studies it was documented that human deciduas 
produced PRL and that its bioactivity was equal to pituitary PRL43. 
PROLACIN SECRETION  
Following synthesis on rough endoplasmic reticulum, PRL is 
packaged in to secretory granules in the Golgi apparatus and PRL release 
occurs via exocytosis. 
MEASUREMENT OF PROLACTIN 
RADIO IMMUNO ASSAY [RIA]44,45: These are double antibody 
assays. 
IMMUNO RADIO METRIC ASSAY[IRMA] 
CHEMILUMINOMETRIC ASSAY[ICMA] 
BIOASSAY: Using Nb2 node rat lymphoma cell assay46. 
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PHYSIOLOGY 
PATTERN OF PROLACTIN SECRETION: 
 Pituitary gland secretes Prolactin hormone in a pulsatile manner. 
The Interval between each pulse of Prolactin hormone secretion is about 
8 minutes47,48. 
Prolactin secretion & sleep49,50: 
Prolactin is secreted in a pulsatile manner 60-90 minutes after the onset of 
sleep.This increases with non – REM sleep.This fall prior to the next 
REM sleep.Lowest levels are found during non – REM sleep.The diurnal 
variation in prolactin secretion is maintained with occurrence of 
sleep.This is maintained in spite of other physiologic influences like 
breast feeding. 
Prolactin secretion & Food intake51,52: 
Secretion of hormone Prolactin starts to rise after food intake.Amino 
acids released from protein digestion cause this increase in secretion. 
Prolactin secretion & aging process: 
No consistent relationship between prolactin secretion and aging could be 
established in various studies. 
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Prolactin secretion & Menstrual cycle53,54: 
Some studies have shown that higher levels during mid – cycle period. 
These studies have also shown lower levels during follicular phase 
compared to luteal phase. 
Prolactin secretion & Pregnancy55,56: 
Prolactin levels progressively increase during pregnancy.This is due to 
the hormone  estrogen.This stimulates the production of prolactin 
hormone from pituitary. 
Prolactin & Lactation56: 
Suckling from new born baby stimulates release of prolactin hormone 
from pituitary gland.Prolactin levels gradually return to baseline over few 
months. 
Prolactin & Stress57: 
Pituitary releases several hormones in response to varying form of 
stress.One of the important hormones released by pituitary in response to 
stress is Prolactin. 
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Prolactin & Thyroid hormones: 
Thyroid hormones act on the lactotroph cells of pituitary and decrease the 
production and subsequent release of prolactin.Serum levels of prolactin 
hormone are increased in hypothyroidism. 
 
NEUROENDOCRINE REGULATION 
 
15 
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Disruption of pituitary stalk: 
Hypothalamus releases a number of prolactin inhibitory factors.These 
prolactin inhibitory factors reach Pituitary by Hypothalamo hypophyseal 
portal vessels.So with disruption of pituitary stalk this negative influence 
gets released.This leads to increase in the release of Prolactin secretion.
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Prolactin Inhibitory Factors [PIFs] 
Dopamine58,59 
Dopamine is found to have an inhibitory effect on the secretion of 
hormone prolactin.  
Gonadotropin Associated Peptide [GAP] 
This is found out to have PRL inhibiting ability in rat experiments.But 
little is known about its bioactivity in human beings. 
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Gamma -  Amino Butyric Acid[GABA] 
Gamma - Amino Butyric Acid causes a reduction in the secretion of 
Prolactin hormone. 
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PROLACTIN RELEASING FACTORS 
Thyrotropin Releasing Hormone [TRH]60 
Thyrotropin Releasing Hormone plays a facilitatory role in the secretion 
of hormone prolactin. 
Vasoactive Intestinal Peptide [VIP]61 
Vasoactive Intestinal Peptide plays a facilitatory role in the secretion of 
hormone prolactin. 
Peptide Histidyl Methionine 
This molecule is a precursor for Vasoactive Intestinal Peptide.This plays 
a facilitatory role in secretion of prolactin. 
Serotonin62 
Serotonin facilitates release of hormone Prolactin.  
Opiod peptides 
In humans, Opiod peptides play a minor facilitatory role in secretion of 
prolactin hormone. 
Growth Hormone Releasing Hormone [GHRH] 
Under some circumstances Growth Hormone Releasing Hormone 
facilitates release of prolactin.  
20 
 
Oxytocin and Vasopressin 
Oxytocin and Vasopressin may be involved in release of prolactin 
mediated through VIP.  
Gonadotropin Releasing Hormone 63 
In some studies GnRH has been found to facilitate release of prolactin 
hormone.  
PRL – releasing peptide 
In some recent studies this peptide has been found to facilitate release of 
prolactin. 
Other neuro active peptides and neurotransmitters 
Neurotensin, Substance P, Cholecystokinin, Somatostatin 
The above mentioned peptides are found to elevate PRL levels in rats but 
their relevance to human beings is not known at present. 
Histamine64 
Histamine can cause a rise in PRL secretion in human beings.This is 
further augmented by H2 blockers and is blocked by H1 blockers. 
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Acetyl choline 
From several studies it is learnt that true role of acetyl choline in PRL 
secretion is unknown. 
PROLACTIN ACTION 
The main function of prolactin in human beings is to facilitate 
lactation.Prolactin facilitates lactation by aiding in breast 
development.Various studies are now showing other biological actions 
for prolactin.But these are yet to be confirmed.  
22 
 
PRL Receptors 
 
 
The PRL and GH receptors are members of the class 1 cytokine 
receptor family.The human genes for the PRL and GH receptors have 
been localized to the short arm of chromosome 5 , sublocalizing to region 
5p13-p14.The human PRL receptor gene has 10 exons ,with exons 3 to 10 
encoding the full length of the long arm of the receptor .The human  PRL 
receptor is 598 amino acids long, has a theoretical , non- glycosylated 
molecular mass of 66.9 kDa and an additional signal peptide of24 amino 
acids .The extracellular domain contains five cysteine residues and three 
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potential N- linked glycosylation sites.There is a hydrophobic region 
corresponding to single transmembrane spanning region of the 
receptor.The human PRL receptor has a much longer intracytoplasmic 
region than does the rat PRL receptor but there is high sequence 
homology between rat ,rabbit and human PRL receptors also between the 
human PRL and GH receptors. Two isoforms of PRL receptor result from 
alternative splicing and differ in the length and composition of 
cytoplasmic tail, being referred to as the long and intermediate forms; the 
short form found in the mouse is not present in humans.PRL binds to its 
receptor with high affinity. Once PRL binds to its receptors there is 
dimerization of the receptor ,a necessary step for activation of 
receptor.PRL receptors are widely distributed ,being found in the breast , 
pituitary , liver , kidney tubules , adrenal cortex , prostate , ovary , testes , 
seminal vesicles , epididymis , intestine , skin , pancreatic islets , 
lymphocytes , lung , myocardium and brain.PRL release caused by 
suckling  increases PRL receptor levels in the breast and liver , resulting 
in a much greater PRL binding activity in lactating animals as compared 
to those not lactating. Hepatic PRL receptor synthesis and numbers 
increase with estrogen treatment in vivo, mediated by the effect of 
estrogen on increasing pituitary PRL secretion. 
24 
 
 
 
 
 
Interaction of PRL binding site 1, encompassing several amino acids 
belonging to helices one and four, with one PRL receptor causes the 
formation of a one – hormone – one receptor complex.  This is a 
prerequisite for PRL binding site 2, involving helices 1 and 3, to interact 
with another receptor, and ultimately causing the formation of the active 
trimeric complex. Signal transduction of the activated receptor involves 
the JAK- Stat pathway .JAK 2 is the particular Janus Kinase involved and 
it is constitutively associated with the PRL receptor.PRL induced 
dimerization of the two receptor molecules brings the two associated JAK 
2molecules close to each other so that they may be activated by 
25 
 
transphosphorylation of tyrosines.The two cytoplasmic domains of the 
receptor must be strictly identical , and the short receptor functions as a 
dominant negative isoform which inhibits activation of receptor complex 
by heterodimerization.The activated JAK 2 phosphorylates tyrosine 
residues on the receptor itself and on three members of the Stat family of 
proteins ,Stat 1 , Stat 3 and Stat 5.Subsequently the hormone receptor 
complex is internalized and localized in the Golgi and vacuoles but the 
physiologic significance of this beyond degradation and scavenging is not 
known. 
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Prolactin effects on Breast65 
PRL, GH, Cortisol, Insulin, Estrogen, Progesterone and Thyroxine all 
contribute to breast development.Prolactin facilitates lobular and alveolar 
tissue development of  breast during pregnancy.Once the breast is fully 
developed and hormonally primed, PRL stimulates the production of milk 
proteins and other components. Suppression of this physiologic 
hyperprolactinemia in the puerperium by bromocriptine causes a rapid 
cessation of milk production. 
Prolactin Effects on Gonadotropin Secretion 
Increased serum prolactin hormone levels inhibit secretion of 
gonodotrophic hormones. 
Prolactin Effects on the ovary 
The roles of hormone prolactin with respect to functions of ovary are less 
well understood. 
Prolactin & Menstrual function66 
Increased serum levels of hormone prolactin is associated with following 
abnormalities 
• Oligomenorrhoea. 
• Amenorrhoea. 
27 
 
• Galactorrhoea. 
• Shortened luteal phase. 
• Infertility. 
• Decreased libido. 
• Orgasmic dysfunction.  
Prolactin & Function of Testes67 
Increased serum levels of prolactin are associated with following 
abnormalities 
• Loss of libido. 
• Impotence. 
• Decreased muscle strength. 
• Decreased beard growth. 
• Sometimes galactorrhoea occurs. 
Prolactin & Cortex of Adrenal gland 
The role of prolactin hormone upon the adrenal gland is less well 
established. 
Prolactin & Bones 
Prolactin hormone might play a role pertaining to mineral metabolism in 
bones.Further studies are needed to confirm this 
28 
 
Prolactin & carbohydrate Metabolism 
The role of prolactin hormone upon the metabolism of carbohydrates is 
less well established.Recent studies have found association between 
increased serum prolactin hormone levels and increased incidence of 
insulin resistance.The insulin resistance seen in patients with increased 
serum levels of prolactin tends to normalize with bromocriptine 
treatment.But further studies are needed to confirm this finding. 
Prolactin & Kidney function 
A number of studies in humans have failed to document a significant role 
for PRL in fluid and electrolyte balance of osmotic stimuli for PRL 
release. 
Prolactin & Immune system  
The clinical relevance of lymphoblastoid PRL and changes in immune 
function in normal individuals and those with hyperprolactinemia is still 
unclear.Nonetheless, the intriguing finding of increased PRL levels in 
many patients with autoimmune rheumatologic diseases merits 
continuous study. 
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PATHOLOGIC STATES OF PROLACTIN SECRETION 
Whenever abnormal serum prolactin levels are detected it should be 
confirmed by repeating the test two or three times. This is because 
Prolactin in human beings is secreted in a pulsatile manner. 
Hypoprolactinemia 
Decreased serum level of hormone prolactin may occur in following 
situations 
• Panhypopituitarism. 
• Post partum pituitary necrosis [Sheehan’s syndrome]. 
• Idiopathic [Very rare]. 
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Hyperprolactinemia  
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Medications 
Neuroleptic agents Phenothiazines. 
Butyrophenones. 
Chlorpromazine. 
Sulpiride. 
Metoclopramide. 
Antiemetic agents. 
Major tranquilizers. 
Anti depressants Tricyclic anti depressants. 
Mono Amine Oxidase inhibitors. 
Selective Serotonin reuptake inhibitors. 
Opiod drugs Opiod abuse. 
Cocaine abuse. 
Antihypertensive drugs Alpha Methyl Dopa. 
ACE inhibitors: Enlapril. 
Reserpine. 
Calcium Channel Blockers Verapamil 
Anti Retro Viral Therapy Protease inhibitors. 
H2 blockers Ranitidine, Cimetidine etc. 
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Stress 
The following conditions are reported to be associated with increased 
serum prolactin levels 
• Transient elevations of serum prolactin hormone level 
occur with physical stress. 
• Minimal transient elevations of serum prolactin level 
are found in association with pschychologic stress. 
• Pseudocyesis.  
Renal disease1,2,3&68. 
Elevated serum prolactin levels are found in chronic kidney disease 
patients.Both male and female patients with chronic kidney disease have 
elevated serum prolactin levels.The following mechanisms are proposed 
for the increase in serum prolactin levels seen in patients with chronic 
kidney disease.There is decreased elimination of Prolactin in patients 
with chronic kidney disease.The metabolism of hormone prolactin is 
reduced in patients with chronic kidney disease.Suppression of prolactin 
hormone in response to dopamine infusion is decreased in patients with 
chronic kidney disease.Some recent evidences are emerging that 
production of hormone prolactin is increased in patients with chronic 
kidney disease.So overall there is disordered regulation of prolactin 
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hormone synthesis and elimination in patients with chronic kidney 
disease.But the exact mechanism behind the rise in serum prolactin levels 
in patients with chronic kidney disease is yet to be identified.Renal 
transplantation for patients with chronic kidney disease brings the 
prolactin levels to normal in these patients.The rise in serum prolactin 
levels seen in patients with chronic kidney disease is a major causative 
factor for the occurrence of hypogonadism, decreased libido and sexual 
dysfunction among male CKD patients.Among female CKD patients the 
rise in serum prolactin levels lead to menstrual irregularities, decreased 
libido, and orgasmic dysfunction. 
Cirrhosis of Liver69 
Serum levels of hormone prolactin are found to be increased in patients 
with cirrhosis of liver.Prolactin response to TRH was found to be normal 
in 75 % of patients with alcoholic cirrhosis .Prolactin response was found 
to be blunted in the remainder.In one study serum prolactin hormone 
levels were found to be elevated in patients with hepatic 
encephalopathy.Defect in the hypothalamic dopamine generation leads to 
the rise in serum prolactin levels in these patients. 
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Hypothyroidism70 
Serum levels of prolactin hormone are increased in patients with 
hypothyroidism.The following mechanisms are proposed for 
this.Hypothyroidism leads to rise in the level of TRH.There is increased 
generation of Vasoactive Intestinal Peptide [VIP] in the pituitary 
gland.The above mechanisms lead to the rise in the serum levels of 
hormone prolactin in this group of patients.Treatment with thyroxine 
brings the serum prolactin hormone levels to normalcy. 
Adrenal insufficiency 
Very rarely adrenal insufficiency can be associated with increase in the 
levels of serum prolactin hormone. 
Neurogenic71 
The rise in serum prolactin hormone levels in following situations 
is because of the stimulation of neuronal pathways that originate in chest 
wall and course through spinal cord. 
• Chest wall lesions. 
• Cervical cord lesions. 
• Post mastectomy. 
• Post thoracotomy. 
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• Chronic spinal cord injuries. 
• Sexual breast stimulation. 
• Suckling. 
Ectopic Prolactin Secretion 
• Ectopic production and secretion of hormone prolactin 
is very rare. 
Diseases of pituitary stalk & Diseases of hypothalamus 
In these disorders control of pituitary by hypothalamus is lost.This leads 
to increase in serum levels of prolactin hormone. 
Idiopathic  hyperprolactinemia 
This diagnosis is made when no specific cause for the elevated serum 
prolactin levels can be identified. 
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CHRONIC KIDNEY DISEASE 
Chronic Kidney Disease [CKD] is defined using following criteria
 
  CKD is classified in to five stages: 
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CLINICAL MANIFESTATIONS: 
 Uremia leads to disturbances in the function of every organ 
system.Various clinical and laboratory manifestation of CKD is as 
follows, 
 With the exception of hypertension, there are usually few clinical 
manifestations during CKD stages 1and 2 [GFR >60 ml/min], the 
presence of proteinuria or haematuria being dependent on the underlying 
cause of kidney disease. Other complications tend to develop 
progressively as the GFR declines below30 ml/min. 
Hypertension 
• Between 50% to 70% of individuals with CKD 
stagesIII to V have hypertension [>140/90 mmHg]. 
Dyslipidemias 
Patients with CKD stage III & more develop a disturbance of lipoprotein 
metabolism.There occurs accumulation of partially metabolized VLDL 
particles.There occurs a disturbance in the maturation of high – density 
lipoprotein.Blood tests typically show hypertriglyceridemia with low 
HDL cholesterol concentrations.Total cholesterol levels are normal. LDL 
– cholesterol levels are normal. But both may be low in the patients with 
concomitant inflammation and malnutrition. 
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Anemia 
• Anemia is seen in CKD stages III to V. 
Causes for anemia in CKD are as follows; 
• Deficiency of erythropoietin. 
• Reduced availability of serum iron. 
• Chronic inflammation. 
Bone and Mineral Metabolism 
Hyperphosphatemia, together with a deficiency of the 1, 25 –dihydroxy 
vitamin D3 contributes to the development of renal bone disease.These 
biochemical and endocrine abnormalities may be evident in patients with 
CKD stage III and are well established in those who reach ESRD.Even 
though they rarely lead to symptomatic bone disease until patients have 
been on dialysis for several years. 
Metabolic acidosis 
The metabolic acidosis associated with chronic kidney disease is caused 
by following factors 
• Failure of hydrogen ion excretion. 
• This is further compounded by bicarbonate loss, particularly 
in interstitial kidney diseases. 
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Malnutrition 
Malnutrition is common among patients on dialysis.Malnutrition may 
occur in those with CKD stages IV to V.Malnutrition is associated with 
increased risk for death.Causes for malnutrition include anorexia, 
acidosis, insulin resistance, inflammation, and urinary protein loss. 
Sodium and Water retention 
Sodium handling by the kidney is altered in CKD although plasma 
sodium concentrations are generally within normal range.Most patients 
with chronic kidney disease develop expansion of extracellular 
volume.They also tend to have retention of sodium in the long run. 
Potassium 
• Hyperkalemia is a common finding in patients with CKD 
stages IV - V. 
Immunity 
Infections contribute significantly to mortality in patients with CKD stage 
V receiving dialysis next only to cardiovascular diseases.This is 
explained in part by the invasive procedures required for the delivery of 
RRT. CKD is a state of chronic immunosuppression with defects in both 
cellular and humoral immunity.The clinical manifestations of these 
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immune defects include increased susceptibility to bacterial infection 
particularly staphylococcal infection.CKD patients are at increased risk 
for reactivation of tuberculosis [Typically with a negative tuberculin skin 
test].CKD patients show inability to eliminate hepatitis B and C virus 
following infections.CKD patients should be immunized against hepatitis 
B as early as possible in an effort to maximize the chance for 
seroconversion. 
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ENDOCRINE ABNORMALITIES IN CKD 
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Thyroid Hormones 
 Total plasma thyroxine [T4] levels may be low, with an associated 
increase in reverse triiodothyronine [T3] as a result of impaired 
conversion of T3 to T4.Loss of thyroid binding globulin may further 
lower total circulating T4 concentrations. However, patients do not 
become clinically hypothyroid, and measurement of thyroid – stimulating 
hormone remains a reliable diagnostic test for hypothyroidism in CKD. 
Growth Hormone 
Plasma growth hormone levels may be elevated in patients with 
CKD stage V because of delayed clearance and alterations in 
hypothalamic – pituitary control. In children, growth retardation may 
result and can be corrected by treatment with exogenous recombinant 
growth hormone given in supraphysiologic doses. 
Insulin 
 Decreased clearance of insulin is balanced by increased peripheral 
resistance to the effects of the hormone. As a result, there are usually no 
clinical manifestations, and patients are not particularly prone to 
hypoglycemia. However in diabetic patients, these effects may lead to a 
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falling requirement for insulin as kidney function deteriorates a trend that 
may be reversed by the initiation of dialysis. 
SEX HORMONES 
Males 
 Prolactin levels are elevated in CKD stage V and may contribute to 
gynaecomastia and sexual dysfunction1,2,3&68 .Testosterone levels are 
often low – normal, and gonadotropins may be raised, implying testicular 
failure82. This is accompanied by poor spermatogenesis, leading to low 
sperm counts and reduced fertility .It is appropriate to prescribe androgen 
replacement treatment if testosterone levels are unequivocally low, not 
least because this may help to prevent osteoporosis. Perhaps the most 
important and sexual problem in males is erectile dysfunction , although 
this is more likely to result from neurologic ,psychological and vascular 
abnormalities than endocrine disturbances and may respond to 
phosphodiesterase type 5 inhibitors such as sildenafil citrate. 
Females 
The pituitary – ovary axis may be disturbed by CKD stages 4 to 583.In 
female chronic kidney disease patients levels of Luteinizing hormone are 
increased.Menstrual Cycles in female CKD patients are therefore often 
anovulatory and may be irregular, or there may be amenorrhoea.Serum 
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levels of hormone prolactin are raised in female CKD patients.Female 
CKD patients may present with infertility.Rarely women receiving 
dialysis conceive and very rarely carry to term. 
HYPERPROLACTINEMIA IN CHRONIC KIDNEY DISEASE 
Males 
 About 40 -70 percent of Male CKD patients have an elevated 
Serum prolactin level74 and the biological activity of this hormone is also 
increased4. As renal failure progresses , elevation of prolactin levels 
seems to correlate with serum creatinine .The normal circadian rhythm of 
prolactin secretion is disturbed in that the characteristic sleep – induced 
secretory bursts are not found , although episodic secretion occurs during 
daytime75. 
Hyperprolactinemia in uremic patients cannot be explained by slightly 
diminished prolactin clearance. A primary mechanism seems to be 
inadequate dopaminergic inhibition of prolactin release from the pituitary 
lactotrophs1. Other authors reported that basal and stimulated prolactin 
concentrations became subnormal after the long – term administration of 
dopaminergic agonists such as bromocriptine, suggesting that prolactin 
secretion in uremic patients can be suppressed at least by chronic 
dopaminergic stimulation. Characteristic stimuli such as thyrotropin – 
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releasing hormone, chlorpromazine, metoclopramide, and arginine or 
insulin – induced hypoglycemia result in blunted prolactin response in 
dialyzed patients. 
In uremic men, hyperprolactinemia is associated with sexual dysfunction, 
loss of libido, impaired erection potency, and infertility5,67. It is not 
known whether the exact mechanism of this disturbed sexual function 
results from a gonadal effect of prolactin or from a hypothalamic 
hypophyseal effect. In uremic patients, the hypothalamic LHRH release is 
apparently suppressed, and high prolactin levels may be implicated in this 
abnormality. However the diminished peripheral clearance of LH 
prevents association of hyperprolactinemia with low LH levels. 
Females  
 Hyperprolactinemia is common among female CKD patients76. 
Compared to healthy controls, the increase of serum prolactin is blunted 
after thyrotropin – releasing hormone stimulation. Hyperprolactinemia is 
a well – known cause of galactorrhoea and gonadal disturbance with 
menstrual irregularities, commonly amenorrhoea, in uremic patients. 
Amenorrhoea is found in patients with regular menstruation. Other 
menstrual irregularities, including anovulatory cycles or 
oligomenorrhoea, are more frequent in hyperprolactinemic patients than 
galactorrhoea, which is the classical symptom of hyperprolactinemia. 
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CORONARY ARTERY HEART DISEASE IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE  
Nearly one half of patients with chronic kidney disease have coronary 
artery heart disease among them. Among patients with chronic kidney 
disease silent coronary artery heart disease is also common. Coronary 
Artery Heart Disease significantly contributes to morbidity and mortality 
in patients with chronic kidney disease.  
ISCHEMIC HEART DISEASE 
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ATHEROMATOUS ISCHEMIC HEART DISEASE 
In humans basal myocardial perfusion tends to remain constant .This is 
maintained irrespective of degree of stenosis of coronary arteries. When 
there is a demand for increased perfusion, a progressive relative decrease 
in perfusion occurs after the degree of stenosis is greater than 40 % or 
greater, and perfusion cannot increase above basal conditions when the 
stenosis is greater than 80% or greater. Therefore, stenosis progressively 
exhausts the coronary vasodilator reserve .The predisposing conditions 
for CKD as well as the CKD itself contributes to the atherosclerotic 
processes. The metabolic disturbances and inflammatory processes in 
CKD facilitate the atherosclerotic process. There is infiltration of arterial 
wall with lipid laden macrophages. These are called as foam cells. There 
is proliferation of fibroblast cells in the arterial wall. There is 
proliferation of smooth muscle cells as well. This results in proliferation 
of atherosclerotic plaque .This atherosclerotic plaque facilitates clot 
formation 
Coronary Artery Disease, characterized by the critical stenosis of 
the major coronary arteries is highly prevalent in the CKD patients.  
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Systemic hypertension is one of the major predisposing factors for 
the atherosclerotic process. Systemic hypertension creates stress to the 
vascular tree. The stress created by systemic hypertension is of two types. 
One is the tensile stress. Another one is shear stress. Both types of stress 
contribute to atherosclerotic process. These stress forces act on the 
vascular tree mainly on the bifurcations. They also act on the orifices of 
vasculature. This leads to facilitation of atherosclerotic process. This 
leads to activation of endothelial cells .This subsequently results in 
secretion of several growth factors. Subsequent effects include alterations 
in cytokine migration, cellular apoptosis, and extracellular matrix 
synthesis. Chronic kidney disease leads to activation of endothelial cells 
in long term.  
In addition to endothelial injury and activation, the vascular 
pathology of chronic uremia includes autocrine and endocrine sequelae 
from a diverse range of seemingly unrelated factors. These include 
Dyslipidemias, Altered platlet function, free radical mediated injury 
because of stress created by oxygen derived free radicals, Decreased 
whole body antioxidant content level, increased serum levels of 
homocysteine, impaired glucose tolerance, occurrence of a state of 
chronic inflammation due to imbalance between various cytokines. 
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Two factors have received particular attention recently in regard to 
their contribution to the development of atheroma in CKD: inflammation 
and vascular calcification. 
Inflammation in general, and C-reactive protein in specifically, 
may contribute directly to the pathogenesis of atherosclerosis and its 
complications both in general and in patients with CKD.CRP has been 
shown to bind to damaged cells, promoting activation of compliment 
system.C Reactive protein binds to atherogenic lipoproteins a potent 
stimulator of tissue factor by monocytes.Epidemiologic studies support 
its pathogenic role as a cardiovascular risk factor in the general 
community. In CKD the sources of elevation in CRP is uncertain. 
Potential sources include back filtration of endotoxin during dialysis, type 
of vascular access, unrecognized infection, and bioincompatibility of 
peritoneal dialysate. CRP levels have been shown to have a powerful 
predictive value for mortality in both haemodialysis and peritoneal 
dialysis recipients and to be an independent predictor of the number of 
atherosclerotic plaques and of intima – media thickness in carotid arteries 
of haemodialysis patients respectively. 
In one study, coronary atherosclerotic plaque morphology in 
patients with CKD was distinguished most readily by composition rather 
than by size or number. 
51 
 
In patients with chronic kidney disease Atherosclerotic plaques are 
characterized by more extensive deposition of calcium ions. This may be 
a contributory factor for the increased rate of complications seen in 
patients with coronary artery disease. Although coronary artery 
calcification is predictive of subsequent coronary events in the general 
population, its clinical significance in patients with CKD is unknown. It 
is possible that the more generalized arterial calcification observed in 
dialysis patients is not predictive of atherosclerotic coronary events, but 
rather is a marker for arteriosclerosis and diminished vascular compliance 
and a risk factor for LV hypertrophy. 
 
NON ATHEROMATOUS ISCHEMIC HEART DISEASE 
 About 25% of dialysis patients with ischemic symptoms do not 
have critical CAD.A significant percentage of predialysis and 
transplantation patients are similarly affected. It is likely that these 
symptoms result from micro vascular disease and the underlying 
cardiomyopathy. In this group of patients there is reduction in the 
maximal dilatory capacity of coronary vessels. In addition there is 
alteration in the oxygen delivery pattern to the myocardium. Together 
these contribute to the ischemia in this patient group.  
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In patients with Chronic Kidney Disease presence of Left Ventricular 
Hypertrophy predisposes these patients to ischemia even in the absence of 
demonstrable atherosclerosis in their coronary vasculature. LV 
hypertrophy is primarily a response to increased tensile stress. This 
requires an overall increase in myocardial energy .This increases the 
demand for oxygen by the myocardium. This increased demand for 
oxygen by the myocardium necessitates dilatation of coronary vessels. If 
atherosclerotic processes have affected the coronary vessels this dilatation 
induced increased flow may not be sufficient to meet the increased 
demand by the myocardium for oxygen. Atherosclerosis of the small 
intramyocardial coronary vasculature is partly responsible for the 
reduction in subendocardial perfusion. 
In patients with chronic kidney disease there is hypertrophy of left 
ventricle myocardium. In this group of patients there is hypertrophy of 
smooth muscle cells situated in the wall of small vessels of coronary 
vasculature. This also predisposes this group of patients for ischemia. In 
patients with chronic kidney disease compliance of coronary arteries are 
reduced. This also predisposes this group of patients for myocardial 
ischemia there is abnormal balance in the high energy phosphate 
compounds in patients with chronic kidney disease. This also contributes 
to ischemic symptoms in them. Secondary hyperparathyroidism which is 
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seen in patients with chronic kidney disease is also a contributory factor 
for ischemia. 
 
RISK FACTORS 
   
  
Age 
 Incidence of chronic kidney disease increases with age which is 
also the case for coronary artery heart disease. The risk for death 
increases by 3% per year of age. 
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Gender 
 The incidence of coronary artery heart disease is more common 
among male patients with chronic kidney disease than female patients. 
When compared to general female population female patients with 
chronic kidney disease are more prone to develop coronary artery heart 
disease 
Smoking 
 Smoking is found to increase the risk of coronary artery heart 
disease among CKD patients. 
Diabetes Mellitus 
 Those chronic kidney disease patients with diabetes are at more 
risk of developing coronary artery heart disease.Those chronic kidney 
disease patients with diabetes also have other risk factors for coronary 
artery disease like dyslipidemia , hypertension , signs of inflammation  , 
increased oxidative stress , & wasting. 
Hypertension 
 Presence of hypertension predicts mortality in patients with 
CKD.The following factors predict the risk of coronary artery heart 
disease in patients with chronic kidney disease. 
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Isolated systolic hypertension 
Increased pulse pressure. 
Dyslipidemia 
 In the CKD population, the relationship among 
hypercholesterolemia, CVD, and mortality is weak.  
Insulin resistance  
 Chronic kidney disease patients with metabolic syndrome exhibit 
varying level of insulin resistance. But the relationship between this 
insulin resistance and risk of coronary artery disease is currently unclear. 
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Nontraditional Risk factors & Risk factors specific to chronic kidney 
disease
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 Chronic kidney Disease itself is now considered an independent 
risk factor for occurrence of coronary artery heart disease .The following 
factors are attributed for this increased risk of coronary artery heart 
disease among patients with chronic kidney disease. 
Oxidative stress  
Inflammation  
 Vascular calcification 
Advanced glycation end products 
In addition several other uremic retention solutes may have pro 
atherogenic properties. Finally healthy kidneys produce substances that 
inhibit CVD and atherogenesis, such as renalase, a soluble monoamine 
oxidase that regulates cardiac function and blood pressure. In ESRD, very 
low plasma concentrations of this putative inhibitor of the sympathetic 
nervous system may contribute to sympathetic overactivity. 
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Oxidative Stress 
  
 
 
 
 
 
 
 
59 
 
 Increased oxidative stress, that is unbalanced surplus of free 
radicals is associated with increased risk for atherosclerosis and increases 
the risk for coronary artery heart disease, chronic kidney disease patients 
are characterized by decreased anti oxidant activity and increased 
prooxidant activity inside the body. Because of poor appetite and 
nutritional status these chronic kidney disease patients also suffer from 
deficiency of antioxidants. 
Inflammation 
 Several studies have demonstrated that chronic kidney disease 
patients are in a state of chronic inflammation. This is evidenced by 
increased level of inflammatory bio markers such as C - reactive protein 
in them. These inflammatory biomarkers are associated with atherogenic 
properties and facilitate atherosclerotic process. 
Endothelial dysfunction 
 Endothelial dysfunction [as evidenced by impaired endothelium – 
dependent vasodilatation ] is  a prominent feature of CKD .The reasons 
for this include a state of chronic inflammation , oxygen dependent free 
radical mediated injury , increased serum levels of homocysteine, 
impaired glucose tolerance , abnormal lipid metabolism and systemic 
hypertension. 
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Anemia  
 Anemia in patients with chronic kidney disease leads to Left 
Ventricular Hypertrophy and over a long term leads to dilatation of left 
ventricle. 
 Secondary Hyperparathyroidism and Mineral Metabolism 
 Disturbance of calcium and phosphate metabolism start as early as 
CKD stage 3 and are potent triggers of accelerated calcifying 
atherosclerosis and arteriosclerosis. 
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 Cardiovascular Calcification  
 
 
Calcification may affect the media of arterial tree, atherosclerotic 
plaques, myocardium, and heart valves. Medial calcification cause 
arterial stiffness and consequently increased pulse pressure. In patients 
with chronic kidney disease calcification of coronary vasculature is very 
common. This calcification of coronary vasculature predicts the long term 
risk of coronary artery heart disease among patients with chronic kidney 
disease. 
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Advanced Glycation End products 
  Advanced Glycation End products accumulate in CKD and may 
contribute to accelerated atherosclerosis and increases the risk of 
coronary artery heart disease among them. 
Hyperhomocysteinemia 
 The prevalence of hyperhomocysteinemia in CKD stage 5 exceeds 
90 %.However the relationship between high homocysteine serum levels 
and CVD in CKD patients has been reported variably. However some 
studies even noted paradoxically lower levels of Homocysteine in uremic 
CVD patients. 
HYPERPROLACTINEMIA IN CKD PATIENTS & RISK  OF  
CAHD 
Chronic kidney disease is associated with a state of chronic inflammation. 
This state of chronic inflammation predisposes these patients to increased 
risk of atherosclerosis and coronary artery heart disease. Recent studies 
are showing that Prolactin may have a role in the process of 
atheroscelrosis.Hyperprolactinemia is found in patients with essential 
hypertension7. Hyperprolactinemia is found in patients during the acute 
phase of coronary syndrome11. During the ischemic stroke episodes also 
hyperprolactinemia is found12,13. Increased serum levels of prolactin are 
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found in men with erectile dysfunction. This increase in serum prolactin 
level positively predicted increased cardiovascular risk among them17. 
Increased serum levels of prolactin hormone found in patients with 
preeclampsia and they play a causative role in the heart failure that 
accompanies post partum cardiomyopathy14,15,16. In some recent studies 
Prolactin receptors were found to be abundantly present atherosclerotic 
plaques18,19 .That too these receptors were found to be abundantly present 
in the macrophages at sites of most prominent inflammation.  
So Hyperprolactinemia in patients with CKD may be a contributing 
factor for the enhanced inflammation seen in CKD patients. 
Hyperprolactinemia in CKD patients may contribute to endothelial 
dysfunction 4.Hyperprolactinemia in CKD may contribute to increased 
atherogenesis4 .It may be a contributing factor for vascular derangements 
seen in CKD patients. Hyperprolactinemia may be a causative factor for 
the worst cardio vascular outcome seen in patients with CKD81. 
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MATERIALS AND METHODS 
 
The study was conducted in 50 patients with chronic kidney 
disease .All of the patients were on Conservative line of treatment. 
The study was conducted in patients admitted in Thanjavur medical 
college hospital between January  2014 to August 2014. 
The patients who fulfill the criteria for CKD and who were on 
Conservative line of treatment were taken in to study. The patients were 
evaluated with ECG and ECHO for presence of Coronary Artery Heart 
Disease and fasting serum prolactin level was measured in them to assess 
the presence of hyperprolactinemia. 
Criteria for Chronic Kidney Disease: 
1. Patients with established Chronic Kidney Disease irrespective of 
etiology. 
2.  Symptoms of uremia for 3 months or more. 
3. Elevated blood urea, serum creatinine and decreased creatinine 
clearance. 
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4. Ultrasound evidence for Chronic Kidney Disease: 
A]  Bilateral contracted kidney – size less than 8 cm in male and 
less than    7cm in females. 
B]  Poor cortico medullary differentiation. 
C]  Type II or III Renal Parenchymal changes. 
5. Following group of patients were excluded from my study: 
 A]  Known patients of hypothyroidism. 
 B]  Known patients of chronic liver disease. 
 C]  Known patients with seizure disorder. 
 D]  Those who are pregnant. 
 E]  Patients with Prolactinomas, Acromegaly & Cushing‘s 
disease. 
 F]  Patients with Craniopharyngioma, Meningiomas, 
Sarcoidosis. 
 G]  Patients with chest wall lesions /surgeries, Spinal cord 
lesions. 
 H]  Patients with adrenal insufficiency. 
 I]  those patients on following medications: 
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Phenothiazines. 
Butyrophenones. 
Chlorpromazine. 
Sulpiride. 
Metoclopramide. 
Antiemetic agents. 
Major tranquilizers. 
Tricyclic anti depressants. 
Mono Amine Oxidase inhibitors. 
Selective Serotonin reuptake inhibitors. 
Opiod abuse. 
Cocaine abuse. 
Alpha Methyl Dopa. 
ACE inhibitors: Enlapril. 
Reserpine. 
Verapamil 
Protease inhibitors. 
H 2Blockers 
 
Detailed clinical history and examination were undertaken in all patients. 
Height and weight and Blood pressure of all patients were recorded. 
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The following investigations were performed in them. 
- Complete Blood Count 
- Peripheral Smear Study 
- ESR 
- Blood sugar fasting, post prandial. 
- HbA1C 
- Blood urea 
- Serum Creatinine 
- Creatinine Clearence 
- Serum Electrolytes 
- Liver Function Test 
- Lipid profile 
- Hbs Ag 
- HCV 
- HIV 
- Urine for albumin, sugar and deposits. 
- Chest – X ray. 
- ECG 
- ECHO 
- USG abdomen 
- Fasting Serum Prolactin level 
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After selecting the patients, about 5 ml of blood sample is collected in a 
non – heparinized bottle and sent for serum prolactin measurement. 
 Quantitative determination of Serum Prolactin was done by Fully 
Automated Bidirectionally Interfaced Chemi Luminescent Immuno 
Assay. 
The Reference range for serum Prolactin includes: 
 Normally menstruating females  : 2.8-29.2 ng/ml. 
 Pregnant women     : 9.7-208.5 ng/ml. 
 Post menopausal women    : 1.8-20.3 ng/ml. 
 Men       : 2.1-17.7 ng/ml. 
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   RESULTS AND OBSERVATIONS 
 
50 Patients with Chronic Kidney Disease who were on conservative line 
of treatment  were studied. 
Among 50 patients 46 patients were male patients and 4 patients were 
female patients. 
Particulars No. of respondents (n=50) 
Percentage 
(100%) 
Male 46 92.0 
Female 4 8.0 
 
 
 
SEX DISTRIBUTION
males
Females
70 
Age distribution 
The patients of chronic kidney disease, in my study were between 29 
years to 70 years. Among 50 patients with chronic kidney disease , 7 
patients were below 40 years of age , 18 patients were in the age group of 
41-50 years, 17 patients were in the age group of 51-60 years , 8 patients 
were 61 years and above. 
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Particulars No. of respondents (n=50) 
Percentage 
(100%) 
Below 40yrs 7 14.0 
41 to 50yrs 18 36.0 
51 to 60yrs 17 34.0 
61yrs & above 8 16.0 
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Observation regarding Chronic Kidney Disease in this study 
 
The duration of Chronic Kidney Disease in this study varied from 6 
months to 8 years. 
The creatinine clearance varied from 4.77 – 46.0.Among the 50 CKD 
patients 31 had creatinine clearance <15 ml/min, 18 patients had 
creatinine clearance 15-30 ml/min, 1 patient had creatinine clearance in 
the range of 30-60ml/min. 
Creatinine 
clearance ml/min 
CKD Stage No. of 
.Respondents 
Percentage 
30-60 III 1 2 
15-30 IV 18 36 
<15 V 31 62 
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Blood Urea level distribution 
Among the 50 patients with CKD Blood urea values varied from 45 
mg/dl to 170 mg/dl. 
 
Blood Urea[mg/dl] No.of.Patients Percentage 
<60 4 8 
60-80 9 18 
80-100 9 18 
100-120 15 30 
120-140 8 16 
>140 5 10 
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Serum creatinine values 
Among the CKD patients serum creatinine values varied between 1.5 
mg/dl to 18.4 mg/dl. 
S.Creatinine level  No. of .Patients Percentage 
<5 24 48 
5-10 18 36 
10-15 6 12 
15-20 2 4 
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Systemic Hypertension 
Classification of systemic hypertension 
Based on the JNC 7 classification  
CATEGORY SYSTOLIC BLOOD 
PRESSURE mmHg 
DIASTOLIC BLOOD 
PRESSURE mmHg 
Normal  <120 <80 
Prehypertension 120-139 80-89 
Stage I 140-159 90-99 
Stage II >160 >100 
 
In the 50 chronic kidney disease patients studied all of them were found 
to be patients of systemic hypertension. 
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Type 2 Diabetes Mellitus 
Patients were diagnosed to have diabetes based on the following criteria: 
 Fasting Plasma Glucose    : 126 mg/dl. 
 2 Hours post prandial plasma glucose  :200 mg/dl. 
 HbA1C     :>6.5%. 
 
Among the 50 CKD patients studied 19 patients were found to be present 
with T2 Diabetes mellitus. 
Particulars No. of respondents (n=50) 
Percentage 
(100%) 
Absent 31 62.0 
Present 19 38.0 
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Dyslipidemias 
Among the 50 CKD patients Dyslipidemias were detected in 16 patients. 
Particulars No. of respondents (n=50) 
Percentage 
(100%) 
Absent 34 68.0 
Present 16 32.0 
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USG Evidence for chronic kidney disease 
Ultrasound features of following were taken as evidence for chronic 
kidney disease 
A] Bilateral contracted kidneys : Size less than 8cm in male patients and 
less than   7 cm in female. 
B] Poor corticomedullary differtiantion. 
C] Type II or III Renal parenchymal changes. 
All 50 patients who have taken part in this study had ultrasound evidence  
For chronic kidney disease. 
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ECG Evidence for presence of CAHD. 
The following were taken as evidence for a CAHD. 
1] ST elevation in men >40 years of age :At J point ≥2 mm in leads 
V2,V3;and >1mm  in all other leads.In men <40 years of age threshold 
for  ST elevation at J point is >2.5mm . 
2]In women ,the threshold for abnormal ST elevation at J point is >1.5 
mm in  leads V2,V3 and >1mm in all other leads. 
3]In right sided leads V3R,V4R threshold for abnormal ST elevation at J 
point is> 0.5mm,in males <30 years of age it is >1mm. 
4]In posterior leads V7,V8,V9 the threshold for abnormal ST elevation at 
J point is 0.5mm. 
A] Any Q wave in leads V2 and V3 >20 ms. 
B] QS complex in leads V2 and V3. 
C] Q wave >30 ms and >0.1 mv in V1-V2 and R: S >1 with a concordant 
positive T       wave in the absence of a conduction defect. 
D] Presence of inverted T waves&associated convex ST segment. 
E] R wave amplitude in lead V 3 is equal to or less than 3 mm. 
F] Reversed R wave progression characterized by R in V4 < R in V3 or R 
in V3 < R in V2 or R in V2 < R in V1or a combination of these changes. 
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Among the 50 patients who were part of this study 18 patients were found 
to have evidence of coronary artery heart disease in ECG. 
 
Particulars 
No. of respondents 
(n=50) 
Percentage 
(100%) 
Absent 32 64.0 
Present 18 36.0 
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ECHO Evidence for CAHD 
The following features on ECHO by M – Mode and 2 – D Echo were 
taken as indicative of CAHD: 
A] Abnormal systolic wall motion. 
B] Systolic wall thickening. 
C] Segmental wall motion abnormalities. 
D] Ejection fraction < 55%. 
Among the 50 patients who were part of this study 18 patients had 
echocardiographic evidence of coronary artery heart disease. 
Particulars No. of respondents (n=50) 
Percentage 
(100%) 
Absent 32 64.0 
Present 18 36.0 
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Serum Prolactin 
Serum prolactin level was measured for the 50 patients with chronic 
kidney disease using fully Automated Bidirectionally Interfaced Chemi 
luminescent Immuno Assay [C.L.I.A]. 
Among the 50 CKD patients 28 patients had raised serum prolactin levels  
Particulars 
No. of respondents 
(n=50) 
Percentage 
(100%) 
Positive 28 56.0 
Negative 22 44.0 
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Descriptive statistics 
Upon summarizing the study of 50 CKD patients following data could be 
obtained. 
Item Min. Max. Mean S.D 
Age 29 70 51.46 9.197 
Symptom Duration ½  8 4.44 2.052 
Urea 45.00 170.00 104.1200 30.30366 
Creatinine 1.50 18.4 7.9500 11.79824 
Creatinine Clearance ml /mm 4.77 46.00 14.5244 8.68455 
Serum Prolactin (ng / ml) 4.27 126.59 33.2369 30.67783 
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Significance of association between serum prolactin levels and age 
distribution of patients with CKD 
  Chi – Square test, Serum Prolactin [ng/ml] 
Age 
Positive Negative Total Statistical 
inference (n=28) (100%) (n=22) (100%) (n=50) (100%) 
Below 
40yrs 3 10.7% 4 18.2% 7 14.0% X2=3.589 
Df=3 
.309>0.05 
Not 
Significant 
41 to 50yrs 13 46.4% 5 22.7% 18 36.0% 
51 to 60yrs 9 32.1% 8 36.4% 17 34.0% 
61yrs & 
above 3 10.7% 5 22.7% 8 16.0% 
 
From statistical analysis serum prolactin levels did not show any 
significant association with age of the CKD patients. 
CHI – SQUARE TEST 
SERUM PROLACTIN (ng / ml) - AGE 
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Significance of association between sex of the CKD patients and 
serum prolactin levels 
  Chi – square test, Serum Prolactin [ng/ml] 
Sex Positive Negative Total Statistical inference (n=28) (100%) (n=22) (100%) (n=50) (100%) 
Male 26 92.9% 20 90.9% 46 92.0% X
2
=.064 Df=1 
.801>0.05 
Not Significant Female 2 7.1% 2 9.1% 4 8.0% 
 
From the statistical analysis of above data there is no significant 
association between serum prolactin levels and sex of the CKD patients. 
 
CHI – SQUARE TEST, SERUM PROLACTIN (ng / ml) - SEX 
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Significance of association between CKD patients with systemic 
hypertension and increased serum prolactin levels 
  Chi – Square Test, Serum Prolactin levels [ng/ml] 
SHT 
Positive Negative Total Statistical 
inference (n=28) (100%) (n=22) (100%) (n=50) (100%) 
Present 28 56% 22 100.0% 50 44.0% - 
 
No statistically significant association could be found between the CKD 
patients with systemic hypertension and increased serum prolactin levels. 
CHI – SQUARE TEST 
SERUM PROLACTIN (ng / ml) - SHT 
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Significance of association between Diabetic patients with chronic 
kidney disease and increased serum prolactin levels 
 Chi – Square Test, Serum Prolactin levels [ng/ml] 
T2 
DM 
Positive Negative Total Statistical 
inference (n=28) (100%) (n=22) (100%) (n=50) (100%) 
Absent 20 71.4% 11 50.0% 31 62.0% 
X2=2.401 
Df=1 
.121>0.05 
Not 
Significant 
Present 8 28.6% 11 50.0% 19 38.0% 
 
No statistically significant association could be established between the 
chronic kidney disease patients with T2 diabetes mellitus and increased 
serum prolactin levels. 
CHI – SQUARE TEST, SERUM PROLACTIN (ng / ml) - T2DM 
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Significance of association between Dyslipidemia in CKD patients 
and increased serum Prolactin levels 
  Chi – square Test, Serum Prolactin [ng/ml] 
DLM 
Hyperprolctinemia 
Positive 
Hyperprolactinemia 
Negative Total Statistical inference (n=28) (100%) (n=22) (100%) (n=50) (100%) 
Absent 21 75.0% 13 59.1% 34 68.0% 
X2=1.433 
Df=1 
.231>0.05 
Not 
Significant 
Present 7 25.0% 9 40.9% 16 32.0% 
 
No statistically significant association could be drawn between 
dyslipidemia in CKD patients and increased serum prolactin levels. 
CHI – SQUARE TEST, SERUM PROLACTIN (ng / ml) – DLM 
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Significance of association between Chronic Kidney Disease and 
increased serum Prolactin levels 
  T – Test, Serum Prolactin levels [ng/ml] 
Hyperprolactinemia Mean  S.D Statistical inference  
Positive (n=28) 3.43 1.620 T=-4.704 Df=48 
.000<0.05 
Significant  
Negative (n=22) 5.73 1.830 
 
According to Statistical analysis of data using T – Test there is a 
significant association between increased serum prolactin levels and 
presence of Chronic Kidney Disease. 
T- TEST, SERUM PROLACTIN – Chronic Kidney Disease 
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Significance of association between blood urea levels in Chronic 
Kidney Disease Patients and increased serum prolactin levels 
  T-Test, Serum Prolactin levels [ng/ml] 
Urea Mean  S.D Statistical inference  
Positive (n=28) 111.1071 31.86934 T=1.887 Df=48 
.065>0.05 
Not Significant  
Negative (n=22) 95.2273 26.24778 
 
As per the T – Test no significant association could be established 
between raised blood urea levels in patients with chronic kidney disease 
and increased serum prolactin levels. 
T- TEST, SERUM PROLACTIN – Urea 
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Significance of association between serum creatinine levels and 
increased serum prolactin levels 
 T –Test, Serum Prolactin levels [ng/ml] 
Creatinine Mean  S.D Statistical inference  
Positive (n=28) 7.4250 4.48757 T=-.352 Df=48 
.727>0.05 
Not Significant  
Negative (n=22) 8.6182 17.26468 
 
According to the results of T test no significant association could be 
established between serum creatinine levels in patients with chronic 
kidney disease and increased serum prolactin levels among them. 
T- TEST, SERUM PROLACTIN – Creatinine 
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Significance of association between creatinine clearance and 
increased serum prolactin levels in patients with chronic kidney 
disease 
T – Test, Serum Prolactin [ng/ml] 
Creatinine Clearence ml /min Mean S.D Statistical inference 
Positive (n=28) 13.4182 9.28529 T=-1.016 Df=48 
.315>0.05 
Not Significant  Negative (n=22) 15.9323 7.83744 
 
As per the statistical analysis using T – Test there was no significant 
association between creatinine clearance in CKD patients and increased 
serum prolactin values in them. 
T- TEST, SERUM PROLACTIN – Creatinine Clearence 
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Significance of association between serum prolactin levels and 
coronary artery heart disease using ECG 
 ECG evidence for  CAHDChi-square test, Serum Prolactin (ng / ml) 
ECG Positive Negative Total Statistical inference (n=28) (100%) (n=22) (100%) (n=50) (100%) 
Absent 11 39.3% 21 95.5% 32 64.0% 
X2=16.870 
Df=1 
.000<0.05 
Significant Present 17 60.7% 1 4.5% 18 36.0% 
 
According to the statistical analysis there was a significant association 
between increased serum prolactin levels and ECG evidence of CAHD. 
CHI – SQUARE TEST, SERUM PROLACTIN (ng / ml) – ECG 
evidence for CAHD 
 
 
0
10
20
30
40
50
60
70
80
90
100
Absent Present 
Pe
rc
e
n
ta
ge
Positive 
Negative
93 
ECHO evidence for CAHD 
Chi-square test, Serum Prolactin (ng / ml) 
Echo 
Positive Negative Total Statistical 
inference (n=28) (100%) (n=22) (100%) (n=50) (100%) 
Absent 11 39.3% 21 95.5% 32 64.0% 
X2=16.870 
Df=1 
.000<0.05 
Significant 
Present 17 60.7% 1 4.5% 18 36.0% 
 
According to the statistical analysis there was a significant association 
between increased serum levels of prolactin and ECHO evidence of 
CAHD. 
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    DISCUSSION 
Hyperprolactinemia in CKD patients 
The kidneys are an important component in regulating endocrine 
systems in the body. The kidneys themselves produce certain hormones 
.Hormones like erythropoietin and calcitriol are examples for the above77. 
Kidneys also play an important role in the metabolism of some hormones 
.Kidneys also play an important role in the degradation of certain 
hormones. Hormones like insulin and cortisol are examples for the above. 
In chronic kidney disease patients following abnormalities are 
noted pertaining to various endocrine systems in the body. There are 
alterations in signal feedback mechanisms of various hormones in the 
body. In addition alteration of hormonal production also occurs. In 
addition changes also occur in transport, protein binding and metabolism 
of hormones. In addition elimination of various hormones also gets 
altered in patients with chronic kidney disease. 
In addition patients with chronic kidney disease also suffer from 
various other conditions. These include Protein energy malnutrition, a 
state of chronic inflammation, multiple drug intake, and presence of 
metabolic acidosis. Most importantly there is disturbance in the 
hypothalamic – pituitary – gonadal axis in patients with chronic kidney 
disease78. 
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One of the major endocrine abnormalities detected in patients with 
chronic kidney disease is increased serum prolactin levels. Several studies 
have shown that serum prolactin levels remain elevated in patients with 
chronic kidney disease .This increase occurs in both male and female 
patients with chronic kidney disease. It has a prevalence of about 30 % to 
65%3,8.This is thought to be mainly due to reduced clearance by the 
kidneys8. There is alteration in the dopaminergic activity in patients with 
chronic kidney disease. Three is increased production of prolactin 
hormone9,10. This also contributes to the increased prolactin levels seen in 
this group of patients. 
In our study we studied 50 patients with chronic kidney disease .In 
our study all patients were on conservative management. Many studies 
have been conducted for correlation between serum prolactin levels in 
CKD patients. 
A Similar study of evaluating serum prolactin levels in chronic 
renal failure patients, CRF patients on haemodialysis and transplant 
recipients was conducted by R Peces & S Casado et all72. In this study R 
Peces & S Casasdo et all72 conducted serum prolactin estimation in 
twelve patients of chronic kidney disease who were on conservative line 
of treatment and thirty patients of chronic kidney disease who were on 
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haemodialysis and nineteen patients of chronic kidney disease who were 
post transplant recipients with a functioning kidney. 
At the end of their study authors have shown that basal levels of  
serum prolactin remain elevated in patients with chronic kidney disease 
.This increased serum levels of hormone prolactin was demonstrated in 
both CKD patients who were on conservative line of treatment and in 
CKD patients who were on haemodialysis.In their study the authors also 
demonstrated that the elevated serum prolactin hormone level showed a 
blunted and delayed response to stimulation with TRH.In this study R 
Peces & S Casado et all  also have shown that Serum prolactin levels 
remain normal in those CKD patients who have received a transplant with 
functioning kidney. In this study authors have attributed the increased 
serum prolactin hormone levels to decreased renal catabolism and 
impaired hypothalamo – pituitary regulation. 
As with other studies in our study also serum prolactin level was 
found to be elevated in 56 % of CKD patients. Remaining 44 % had 
normal serum prolactin levels. 
A similar study of evaluating hyperprolactinemia and impaired 
pituitary response to suppression and stimulation in patients with chronic 
kidney disease was conducted by V.S.Lim , S.C.Kathpalia and L. 
Frohaman1 .In this study authors also analyzed the reversibility of the 
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above mentioned abnormalities with Renal transplantation. In this study 
authors have demonstrated increased basal serum prolactin levels in 
patients with chronic kidney disease .In this study authors also have 
demonstrated that Prolactin hormone showed lack of responsiveness to 
suppressive as well as stimulatory agents .They attributed this lack of 
responsiveness to pathology at the pituitary either at the level of receptor 
binding or a post receptor level. 
A similar study of Abnormalities in the regulation of serum 
prolactin hormone levels in patients with chronic kidney disease was 
conducted by German Ramirez, William M. O Neill, JR.H.Allan Bloomer 
and William Jubiz77.In this study authors have studied the serum levels of 
prolactin hormone in patients with chronic kidney disease who were 
treated with haemodialysis.They also studied the regulation of prolactin 
hormone secretion in patients with chronic  kidney disease.At the end of 
their study authors have concluded that basal serum levels of prolactin 
hormone remained elevated in patients with chronic kidney disease 
.Authors also demonstrated that this increased serum prolactin levels 
failed to suppress significantly following the administration of L – 
Dopa.This increased serum prolactin hormone levels also failed to show 
an increase in response to chlorpromazine and also to thryotropin 
releasing hormone.They concluded that serum prolactin hormone levels 
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increase in patients with chronic kidney disease and it is also abnormally 
regulated in these population. 
Our study is consistent with results of above mentioned studies in 
that in our study basal serum levels of hormone prolactin remained 
elevated in 56 % of CKD patients. There was a statistically significant 
association between increased serum prolactin levels and presence of 
chronic kidney disease. 
Hyperprolactinemia and the risk of Coronary Artery Heart Disease 
From several studies conducted recently it has been shown that 
increased serum prolactin levels are commonly found abnormality in 
patients with Chronic Kidney Disease. However there are only limited 
numbers of studies available regarding the implications of this increased 
serum prolactin levels in patients with chronic kidney disease. The only 
few studies conducted in last decade on the consequences of this 
increased serum prolactin levels in patients with chronic kidney disease 
were mainly focused on the reproductive and sexual dysfunction . 
 Evidences from several studies conducted in non – renal 
population are accumulating which shows Prolactin may have several 
other actions other than what has already been well described. From these 
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studies it has been shown that Prolactin is having actions on several other 
biological systems as well which accelerate the process of atherosclerosis. 
Increased serum levels of hormone prolactin have been observed in 
patients with essential hypertension7,79. 
The role of prolactin in essential hypertension was studied by J R 
Sowers, M Nyby et all79 in their study, Dopaminergic control of prolactin 
and blood pressure: Altered control in essential hypertension. In their 
study authors examined the influence of dopamine on plasma 
catecholamine levels and plasma prolactin levels .The authors studied the 
mean arterial pressure response to upright posture .They also studied the 
mean arterial pressure response to isometric hand grip exercise. They 
analyzed the recumbent circadian prolactin and mean arterial pressure 
patterns in essential hypertension. In their study authors observed that a 
prolactin response to posture and isometric exercise in patients with 
essential hypertension. This was not observed in normotensive 
individuals. In this study authors also observed mean prolactin levels in 
patients with essential hypertension to be significantly higher over a 24 - 
hour recumbent period. In their study authors also observed that 
Treatment with bromocriptine had a lowering effect on mean arterial 
pressure levels throughout the 24 hours in the hypertensive 
group.Bromocriptine also eliminated the circadian rhythm of Prolactin 
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secretion. Thus at the end of their study authors conclude that circadian 
variations in prolactin secretion and blood pressure appear to be 
modulated by a central and / or peripheral dopaminergic mechanism 
.Decreased dopaminergic activity in essential hypertension may account, 
in part, for aberrances in prolactin secretion and systemic hypertension. 
In addition it has been shown that prolactin plays a role in systemic 
hypertension in post menopausal women. It has also been shown that 
prolactin plays a role in arterial stiffness in post menopausal women. 
This was studied by George  A .Georgiopoulos, Kimon S. 
Stamatelopoulos , Irene Lambrinoudaki et all80 ;They studied the 
relationship between increased serum prolactin levels and preclinical 
atherosclerosis in menopausal women with cardiovascular risk factors.In 
this study authors have demonstrated significant correlation between 
increased serum prolactin levels and arterial blood pressure.In this study 
significant association was found between increased serum prolactin 
levels and central aortic systolic blood pressure.Significant correlation 
was also demonstrated between increased serum prolactin levels and 
central aortic diastolic blood pressure. Increased serum prolactin levels 
also had significant correlation with aortic pulse wave velocity. Aortic 
pulse wave velocity is a marker for aortic stiffness. By statistical analysis 
increased serum prolactin levels predicted the long term risk of systemic 
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hypertension .It also predicted the long term risk of aortic stiffness. At the 
end of this study authors have arrived at a conclusion that increased 
serum prolactin levels play a role in accelerating the process of 
arteriosclerosis in females with early menopause. Possible mechanism 
behind this may be by prolactin affecting central and peripheral blood 
pressure and by facilitating the arterial stiffness. 
From several studies it has been shown that serum prolactin levels 
increase in patients during the acute phase of coronary syndromes11. In 
addition increased serum prolactin levels have also been demonstrated in 
patients with ischemic stroke12,13. 
In a study by Robin Haring ,Nele Friedrich et all81 positive 
association of serum prolactin concentrations with all – cause and 
cardiovascular mortality was studied by authors. In their study authors 
reported an independent positive association of serum prolactin 
concentrations with all – cause mortality. Authors also established an 
independent positive association between serum prolactin concentration 
and cardiovascular mortality. 
Raised serum prolactin has been shown to play a causative role in 
hypertensive complications of patients with preeclampsia14,15. In addition 
it has been shown that increased serum prolactin plays a causative role in 
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the development of heart failure that accompanies peri and post partum 
cardiomyopathy16. 
In another study increased serum prolactin levels predicted adverse 
cardio vascular events in male patients with erectile dysfunction17. 
In another study by Anne Q Reuwer , Marco Van Eijk ,et all18 the 
authors demonstrated prolactin receptors in the atherosclerotic plaques 
which they obtained from human carotid arteries. In this study through in 
situ hybridization techniques authors demonstrated the presence of 
prolactin receptors in mononuclear cells of atherosclerotic plaques. Using 
immunohistochemical analysis and immunoelectron microscopy authors 
demonstrated the abundant presence of prolactin receptors in the 
macrophages near the lipid core of the atherosclerotic plaques .Prolactin 
receptors were also abundantly detected in the macrophages near the 
shoulder region of the atherosclerotic plaques. At the end of their study 
authors conclude that Prolactin receptors are increasingly expressed in 
macrophages of the atherosclerotic plaques at sites of most prominent 
inflammation. Finally authors conclude that prolactin receptor signaling 
contributes to the local inflammatory response within the atherosclerotic 
plaque .This aggravates the process of atherogenesis. 
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In another study by Dilek Yavuz, Oguzhan Deyneli, Ishan Akpinar et all 
6Endothelial function, insulin sensitivity and inflammatory markers in 
hyperprolactinemic pre – menopausal women were studied in detail6. In 
this 16 hyperprolactinemic patients were taken for study. They studied 
insulin sensitivity among the study group. Endothelial function was 
studied using flow mediated dilatation technique. The authors finally 
concluded that hyperprolactinemic state was associated with impaired 
endothelial function .It was also shown to be associated with decreased 
insulin sensitivity. Both the above factors contribute to process of 
atherosclerosis. The increased serum prolactin levels may contribute to 
the early atherosclerosis in this patient group. Correction of this increased 
serum prolactin level was associated with improvement in endothelial 
function .It also improves insulin sensitivity among them. 
Hyperprolactinemia in CKD patients and the risk of coronary artery 
heart disease 
Prolactin levels, endothelial dysfunction and the risk of cardiovascular 
events and mortality in patients with CKD were extensively studied by 
Juan jesus carrero, John Kyriazis ,Alper Sonmez et all4. 
 We conducted an observational study .In our study we evaluated 
serum prolactin levels in 50 patients with chronic kidney disease and we 
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further evaluated the association between increased serum prolactin levels 
and the risk of coronary artery heart disease. 
 In the study by Juan Jesus Carrero et all4 the authors conducted an 
observational study in two cohorts.One cohort of 457 nondialyzed CKD 
patients and another cohort of 173 CKD patients who were on 
haemodialysis.In their study authors measured the serum levels of 
hormone prolactin in both cohorts. To assess the cardiovascular risk in 
non – dialyzed CKD patients’ authors conducted assessments with Flow 
mediated dilatation [FMD] and Carotid intima – media thickness [IMT], 
In Chronic Kidney Disease patients who were on haemodialysis authors 
did the assessment with Pulse Wave Velocity [PWV]. 
 In their study Authors demonstrated an increase in serum prolactin 
levels in both non – dialyzed CKD patients and in CKD patients who 
were on haemodialysis.In their study, in non – dialyzed CKD patients, 
every 10 ng/ml increase in serum prolactin raised the risk of suffering an 
adverse cardiovascular  
Event by 27 %.It had a hazard ratio of 1.27.In their study authors have 
shown in second cohort of CKD patients who were on haemodialysis 
,every 10 ng/ml increase in serum prolactin level increased the risk of 
mortality due to cardiovascular disease by 15 %.It had a hazard ratio of 
1.15.In their study authors also described an association between 
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hyperprolactinemia and endothelial dysfunction as measured by flow – 
mediated dilatation [FMD].They also described an association between 
hyperprolactinemia and arterial stiffness as assessed by Pulse wave 
velocity. 
 In our study we did an estimation of serum prolactin level in 50 
chronic kidney disease patient’s .Among the 50 CKD patients 28 had 
elevated serum prolactin levels which was about 56%.Increased serum 
prolactin levels had an statistically significant association with presence 
of chronic kidney disease. 
 We further did an analysis about presence of coronary artery heart 
disease in patients with increased serum prolactin levels .We did that by 
doing ECG and ECHO analysis of patients who show an increased serum 
prolactin level. 
 In our study among the 28 CKD patients with hyperprolactinemia 
17 patients had coronary Artery Heart Disease as diagnosed by using 
ECG & ECHO which is about 60.7%.This also showed a statistically 
significant association to exist between hyperprolactinemic CKD patients 
and occurrence of CAHD among them. 
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LIMITATIONS OF OUR STUDY 
• Our study was observational in nature. 
• In our study we could not determine Prolactin is a risk factor per se 
or whether it is an intermediate in larger pathological pathway. 
• Increased serum prolactin level in patients with chronic kidney 
disease leads to decreased gonadotropin levels with consequent 
testosterone deficiency. This reduction in testosterone may also be 
a contributory factor for accelerated atherosclerosis and increased 
risk of CAHD. 
• Increased serum levels of hormone prolactin may also be a 
consequence of reduced dopaminergic activity. This would have 
resulted in increased noradrenaline release .This would have 
resulted in endothelial dysfunction and adverse cardiovascular 
outcome. 
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CONCLUSION 
50 patients of chronic kidney disease who were on conservative line of 
treatment were taken for study. Serum prolactin levels were measured in 
them .They were evaluated for presence of Coronary Artery Heart 
Disease using ECG and ECHO. The association between 
hyperprolactinemia in CKD patients and occurrence of Coronary Artery 
Heart Disease among them was studied. 
The following conclusions were arrived from our study 
• Chronic Kidney Disease is associated with increased serum levels 
of hormone prolactin [Hyperprolactinemia]. 
• Hyperprolactinemia could be detected in 56 % of our study group 
of patients with chronic kidney disease. 
• Among the CKD patients with hyperprolactinemia about 60.7% 
had evidence of Coronary Artery Heart Disease when evaluated 
using ECG and ECHO. 
• From our study we could conclude that hyperprolactinemia in 
patients with chronic kidney disease may be a risk factor for future 
risk of Coronary Artery Heart Disease. 
• Further studies are needed to confirm this finding.  
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PROFORMA 
A STUDY ON SERUM PROLACTIN LEVELS IN CKD PATIENTS &IT’S 
CORRELATION WITH CORONARY ARTERY HEART DISEASE 
 
NAME:       AGE:    
 
SEX:        IP NO:  
 
 
History Of:  
  Periorbital oedema 
   
  Reduced urine output 
 
  Pedal oedema,  
 
  Difficulty in breathing  
                        
                        Headache 
 
  Seizures 
   
   Current pregnancy 
 
  Chronic Liver Disease 
   Hypothyroidism 
 
  Seizure disorder 
 
  Chronic drug intake 
 
  Chest wall surgery 
  Any surgery on the breast 
  H/O Galactorrhoea 
 
  Trauma 
  Menstrual history 
 
Examination:  
                       
                      Anemia 
 
  Clubbing  
 
  Cyanosis  
 
  Jaundice 
 
  Pedal  oedema 
   Lymphadenopathy 
 
   
Vital signs: Pulse rate   Blood pressure: 
 
Cardiovascular system: Pericardial rub 
    
        Pericardial effusion  
 
Respiratory system:      Pleural rub / Effusion/ Pneumonitis  
 
Abdomen          :      Hepatomegaly/Ascites 
 
Central Nervous System: Focal neurological deficit  
 
Investigations: 
 
  Complete Blood count                         
                       ESR 
  Peripheral smear study 
  Blood sugar – Fasting, 2 hours postprandial 
  HbA1C 
                       Blood Urea 
  Serum Creatinine    
  Serum electrolytes 
  Lipid Profile 
                        LFT 
Chest x-ray 
ECG 
HbsAg 
HCV 
HIV 
 
 
  USG Abdomen  
 
 
  
  ECHO 
 
 
 
 
 
 
  Fasting Serum Prolactin Level: 
 
S. 
No 
I.P.Nu
mber Age Sex 
Symptom 
Duration 
SH
T 
T2 
DM 
DL
M 
 
Renal 
Parameters Creatinine 
Clearence 
ml/min 
USG 
Abdomen ECG ECHO 
Serum 
prolactin 
[ng/ml] 
 
 
 
 
Evidence for 
CKD 
Evidence 
for 
CAHD 
Evidenc
e for 
CAHD. Urea 
Creat
inine 
1 39746 55 M 3 years P P P 80 3.1 23 Present Present Present 32.94 
2 33156 50 M 2 Years P A P 135 11.0 5.8 Present Absent 
 
Absent 
 
65.97 
3 33695 48 M 3 Years P P A 98 4.2 18.25 Present Absent 
 
Absent 
 
10.11 
4 39829 41 M 1 Year P A P 170 18.4 5.5 Present Present Present 37.86 
5 40209 61 M 3 Years P P A 82 2.0 27.43 Present Absent 
 
Absent 
 
9.28 
6 34509 37 M 2 Years P P P 132 11.4 7.53 Present Absent 
 
Absent 
 
19.46 
7 39753 45 M 3 years P A A 66 2.9 22.75 Present Absent 
 
Absent 
 
23.66 
8 40300 34 M 6 months P A A 45 1.6 46 Present Present Present 
53.23 
 
 
9 40251 64 M 1 Year P A A 130 10.8 5.86 Present Absent 
 
Absent 
 
31.41 
10 36380 53 M 2 Years P A A 66 2.4 25.17 Present Absent 
 
Absent 
 
45.58 
 
 
 
 
 S. 
No 
I.P.Num 
ber 
Age Sex 
Symptom 
Duration 
SH
T 
T2 
D
M 
DLM 
Renal 
Parameters 
Creatinine 
Clearence 
USG 
Abdomen 
ECG ECHO Serum 
Prolactin 
[ng/ml] 
 
 
 
Evidence 
for CAHD 
Evidence 
for CAHD 
 
Evidence 
for CKD Urea 
Creat
inine 
 
11 38664 47 M 4 Years P P A 78 4.4 15 Present Present Present 80.49 
12 32323 50 M 3 Years P A P 120 9.0 8.33 Present 
Absent 
 
Absent 
 
25.48 
13 39733 55 M 8 Years P P P 90 3.3 17.89 Present 
Absent 
 
Absent 
 
9.2 
14 39702 29 F 5 Years P A A 102 7.0 11.01 Present 
Absent 
 
Absent 
 
15.02 
15 40244 55 M 5 Years P P A 105 7.3 9.7 Present Present Present 55.34 
16 39846 60 M 7 Years P P A 108 6.8 8.17 Present 
Absent 
 
Absent 
 
12.66 
17 39859 55 M 7 Years P A A 50 1.6 29.51 Present 
Absent 
 
Absent 
 
10 
18 40683 38 M 3 Years P A A 69 2.6 27 Present Present Present 24.33 
19 40662 50 M 2 Years 
 
P 
A A 138 7.6 9.87 Present 
Absent 
 
Absent 
 
29.14 
20 39875 65 M 7 Years P A P 50 1.5 27.78 Present 
Absent 
 
Absent 
 
7.26 
 
 
 
  
 
S. 
No 
I.P.Num
ber 
Ag
e 
Se
x 
Sympt
om 
Durati
on 
S
H
T 
T2 
D
M 
DLM 
Renal Parameters 
Creati
nine 
Cleare
nce 
USG 
Abdom
en 
ECG ECHO 
Serum 
Prolactin 
[ng/ml] 
 
 
 
Urea 
 
Creatin
ine 
 
 
Evidenc
e for 
CKD 
Evidence 
for CAHD 
 
Evidence 
for CAHD 
 
 
21 39172 54 M 2 Years P A P 92 3.4 17.57 Present Present Present 36.93 
22 35342 46 M 6 Years P P A 90 6.0 13.06 Present 
Absent 
 
Absent 
 
5.73 
23 36321 49 M 6 Years P A A 162 15.9 4.77 Present 
Absent 
 
Absent 
 
91.1 
24 40339 53 M 6 Years P A P 120 7.0 8.63 Present 
Absent 
 
Absent 
 
13.29 
25 39026 58 M 3Years P P A 105 8.4 8.13 Present Present Present 34.44 
26 41478 60 M 4 Years P P A 80 4 16.67 Present 
Absent 
 
Absent 
 
110.1 
27 40579 33 M 7 Years P P P 62 2.0 29.72 Present 
Absent 
 
Absent 
 
4.27 
28 28171 60 M 2 Years P A A 100 2.2 25 Present Present Present 45.28 
29 23464 48 M 6 Years P A A 102 7.0 10.95 Present Present Present 21.94 
30 41169 60 M 8 Years P A A 99 4.0 19.44 Present 
Absent 
 
Absent 
 
8.2 
S. 
No 
I.P.Nu
mber 
Age 
Se
x 
Symp
tom 
Durat
ion 
SH
T 
T2 
DM 
DL
M 
Renal Parameters 
 
Creatin
ine 
Clearen
ce 
USG 
Abdom
en 
ECG ECHO 
 
 
Serum 
Prolactin 
[ng/ml] 
Serum 
Prolactin 
[ng/ml] 
 
Evidenc
e for 
CAHD 
 
Evidence 
for CAHD 
 
Evidenc
e for 
CKD Urea 
Creatinin
e 
31 36572 50 F 
5 
Years 
P P A 116 8.2 9.07 Present Present Present 8.24 8.24 
32 37484 54 M 
5 
Years 
P A A 126 8.6 8.33 Present Present Present 126.59 126.59 
33 40586 64 M 
6 
Years 
P A P 72 2.7 22.02 Present 
Absent 
 
Absent 
 
7.47 
 
7.47 
34 39276 55 M 
3 
Years 
P P A 120 4.5 13.12 Present Present Present 22.05 22.05 
35 40251 64 M 
5 
Years 
P P A 140 11.2 6.6 Present 
Absent 
 
Absent 
 
61.56 
 
61.56 
36 36275 50 M 
5 
Years 
P A P 122 8.8 8.52 Present 
Absent 
 
Absent 
 
39.66 
 
39.66 
37 38133 44 M 
4 
Years 
P A A 112 9.9 8.08 Present Present Present 23.17 23.17 
38 35702 60 M 
6 
Years 
P A A 120 7.7 7.22 Present 
Absent 
 
Absent 
 
 
5.94 
5.94 
39 39376 48 M 
7 
Years 
P P P 142 8.5 9.02 Present 
Absent 
 
Absent 
 
7.6 
 
7.6 
40 31568 43 M 
5 
Years 
P A A 132 9.4 8.6 Present Present Present 85.83 85.83 
 
 
 
 S. 
No 
I.P.Number Age 
Se
x 
Sympto
m 
Duratio
n 
SHT 
T2 
D
M 
DL
M 
 
Renal Parameters 
Creatinine 
Clearence 
USG 
Abdomen 
ECG ECHO 
Serum 
Prolactin 
[ng/ml] 
Evidence 
for CAHD 
 
Evidence 
for 
CAHD 
 
Evidence 
for CKD 
Urea Creatinine  
41 34581 50 M 2 Years P A A 150 14.4 5.5 Present present Present 57.82 
42 35676 60 M 6 Years P P A 68 2.4 23.15 Present 
Absent 
 
Absent 
 
11.17 
43 36093 40 M 7 Years P A P 120 6.0 11.57 Present 
Absent 
 
Absent 
 
12.21 
44 55342 43 F 3 Years P A A 90 3.8 12.0 Present Present Present 103.43 
45 36214 48 M 3 Years P A A 102 5.0 12.78 Present 
Absent 
 
Absent 
 
4.28 
46 35097 62 F 
4 Years 
 
P P A 120 3.2 11.0 Present Present Present 64.96 
47 34154 40 M 7 Years P A P 156 12.1 6.89 Present 
Absent 
 
Absent 
 
24.4 
48 36378 53 M 3 Years P A P 116 8.5 7.11 Present 
Absent 
 
Absent 
 
13.6535 
49 35386 62 M 6 Years P P A 60 2.8 19.35 Present 
Absent 
 
Absent 
 
5.62 
50 35550 70 M 8 Years P A A 96 4.5 10.8 Present 
Absent 
 
Absent 
 
6.49 
 
     
 ABBREVIATIONS USED IN MASTER CHART 
 
S.NO SERIAL NUMBER 
I.P.NUMBER IN PATIENT NUMBER 
SHT SYSTEMIC HYPERTENSION 
T2DM TYPE 2 DIABETES MELLITUS 
DLM DYSLIPIDEMIA 
USG ABDOMEN ULTRASONOGRAM ABDOMEN 
CKD CHRONIC KIDNEY DISEASE 
CAHD CORONARY ARTERY HEART DISEASE 
ECG ELECTROCARDIOGRAM 
ECHO ECHOCARDIOGRAM 
P PRESENT 
A ABSENT 
 
 


